Published in Br J Haematol on July 01, 1998
An analysis of 8 cases of factor X deficiency. Indian J Hematol Blood Transfus (2008) 0.84
Toxicity and recovery in the pregnant mouse after gestational exposure to the cyanobacterial toxin, cylindrospermopsin. J Appl Toxicol (2010) 0.76
Clinical profile of patients with rare inherited coagulation disorders: a retrospective analysis of 67 patients from northern India. Mediterr J Hematol Infect Dis (2012) 0.76
Membranoproliferative glomerulonephritis and a rare bleeding disorder: Factor X deficiency. Int Urol Nephrol (2010) 0.75
Near fatal spontaneous intraperitoneal bleeding: A rare manifestation in a congenital factor X deficiency carrier. Indian J Crit Care Med (2015) 0.75
Hereditary Factor X (Stuart-Prower Factor) Deficiency. Med J Armed Forces India (2011) 0.75
Inherited Factor X (Stuart-Prower Factor) deficiency and its management. Med J Armed Forces India (2014) 0.75
Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma. Clin Case Rep (2015) 0.75
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Genetic transformation of Streptococcus mutans. Infect Immun (1981) 4.13
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Genetic transformation of putative cariogenic properties in Streptococcus mutans. Infect Immun (1983) 2.66
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Isolation, sequence determination and expression in Escherichia coli of the isopenicillin N synthetase gene from Cephalosporium acremonium. Nature (1985) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Effect of filtrates from transformable and nontransformable streptococci on the transformation of streptococci. J Bacteriol (1966) 1.86
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Myofilament lattice spacing as a function of sarcomere length in isolated rat myocardium. Am J Physiol Heart Circ Physiol (2000) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Transformability of streptomycin-resistant group H streptococci. J Bacteriol (1968) 1.50
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Rare coagulation disorders. Thromb Haemost (1999) 1.46
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost (1996) 1.43
Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke (1996) 1.42
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost (1991) 1.40
Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol (1993) 1.40
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach. Blood Coagul Fibrinolysis (1996) 1.39
Frequency of factor V Arg506 Gln in Italians. Thromb Haemost (1996) 1.39
Calibration of local systems with lyophilized calibrant plasmas improves the interlaboratory variability of the INR in the Italian external quality assessment scheme. Thromb Haemost (1999) 1.38
A novel GJA8 mutation in an Iranian family with progressive autosomal dominant congenital nuclear cataract. J Med Genet (2003) 1.38
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol (1999) 1.38
Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost (1994) 1.38
A simple effective splinting technique for the mallet finger. Am J Orthop (Belle Mead NJ) (2000) 1.38
Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med (1983) 1.38
Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol (1995) 1.37
In vivo and in vitro models of demyelinating diseases. III. JHM virus infection of rats. Arch Neurol (1980) 1.37
Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia (2006) 1.36
Intolerance to protein hydrolysate infant formulas: an underrecognized cause of gastrointestinal symptoms in infants. J Pediatr (1997) 1.35
Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant. Thromb Haemost (1983) 1.34
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Coronary artery bypass grafting in an achondroplastic dwarf. Tex Heart Inst J (1995) 1.32
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood (1992) 1.31
Deficiencies of protein C, an inhibitor of blood coagulation. Lancet (1982) 1.28
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia (2008) 1.28
Platelet volume and shape in relation to aggregation and adhesion. Br J Haematol (1967) 1.27
Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer (2000) 1.26
Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med (2000) 1.26
Asymptomatic liver disease in haemophiliacs. J Clin Pathol (1975) 1.26
(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem (1996) 1.23
The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood (1992) 1.22
Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia (2002) 1.21
Mapping of a cloned glucosyltransferase gene in Streptococcus mutans. Infect Immun (1985) 1.21
Binding of fibrinogen to human monocytes. J Clin Invest (1986) 1.20
Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol (1992) 1.20
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
High rate of complications associated with peripherally inserted central venous catheters in patients with solid tumours. Intern Med J (2004) 1.19
Risk of cerebral vein thrombosis and oral contraceptives. Lancet (1998) 1.18
Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol (1989) 1.18
Rare coagulation deficiencies. Haemophilia (2002) 1.18
Resolving disagreements in the patient-physician relationship: tools for improving communication in managed care. JAMA (1999) 1.17
Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet (1997) 1.17
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost (1997) 1.17
Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost (1999) 1.17
Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood (1997) 1.15
Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol (1999) 1.13
Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol (1999) 1.12
Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand's disease. Br J Haematol (1976) 1.12
Factor VIII-related properties in platelets from patients with von Willebrand's disease. J Lab Clin Med (1978) 1.12
Effect of competence induction on macromolecular synthesis in a group H streptococcus. J Bacteriol (1974) 1.10
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia (2008) 1.10
Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis. Thromb Haemost (1985) 1.10